Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Vor Biopharma Inc. Common Stock

VOR

Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.

Last trade $17.95
Day change -$1.02 (-5.38%)
Day range $17.75 – $19.70
Volume 495,360
Market cap $1.17B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.17B
Price / earnings
0.86×
Price / book
-8.5×
Price / sales
—
EV / sales
—
EV / EBITDA
-6.13×

Profitability

Earnings per share
$22.04
Return on assets
272.76%
Return on equity
-986.88%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-0×
Current ratio
13.5×
Quick ratio
13.5×
Cash ratio
2.17×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$119.68M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for VOR, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$23.91M$21.93M$17.57M$16.77M$13.97M$12.79M$6.59M$5.96M
Research and development$34.53M$25.92M$17.6M$19.19M$14.14M$261.5M$26.7M$25.35M
Total operating expenses$58.44M$47.85M$35.16M$35.96M$28.11M$274.28M$33.29M$31.31M
Operating income-$58.44M-$47.85M-$35.16M-$35.96M-$28.11M-$274.28M-$33.29M-$31.31M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$86.73M-$62.81M-$219.59M$1.72B-$812.68M-$1.57B-$32.49M-$30.71M
Income taxes$0$0$0$0$0$0$0$0
Net income-$86.73M-$62.81M-$219.59M$1.72B-$812.68M-$1.57B-$32.49M-$30.71M
Net income attributable to common shareholders-$86.73M-$62.81M-$219.59M$1.72B-$812.68M-$1.57B-$32.49M-$30.71M
EBITDA-$58.41M-$47.82M-$35.13M-$35.94M-$28.11M-$272.25M-$32.47M-$30.45M
Basic earnings per share-$1.45-$1.16-$5.11$84.87-$121.63-$251.24-$5.21-$8.77
Diluted earnings per share-$1.45-$1.16-$5.11$84.87-$121.63-$251.24-$5.21-$8.77

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Vor Bio announced completion of enrollment in its Phase 3 UPSTREAM MG trial for telitacicept in generalized myasthenia gravis, with topline results expected in 1H27. The company expanded into ocular myasthenia gravis with a new Phase 3 trial and continues enrollment in primary Sjögren's disease. With $481.6 million in cash, the company projects runway into early 2029. Additional data from the TELIGAN trial showed telitacicept demonstrated durable kidney function preservation in IgA nephropathy.

GlobeNewswire Inc.

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio announced the grant of stock options for 59,250 shares and RSUs for 12,550 shares to 9 newly hired employees on October 1, 2026, as material inducements to employment. The options have a 10-year term with an exercise price of $18.06 per share and vest over four years. The company continues advancing telitacicept through Phase 3 clinical development for autoimmune diseases, with enrollment completed in the UPSTREAM MG trial and expansion into ocular myasthenia gravis.

GlobeNewswire Inc.

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio announced on July 1, 2026, that it granted stock options to purchase 71,200 shares and RSUs representing 15,150 shares to 7 newly hired employees as material inducements to employment. The options have a 10-year term with an exercise price of $18.39 per share and vest over four years, with RSUs vesting quarterly over the same period.

GlobeNewswire Inc.

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio announced the grant of stock options to purchase 61,050 shares and RSUs representing 12,900 shares to 10 newly hired employees on June 1, 2026. The stock options have a 10-year term with an exercise price of $14.57 per share and vest over four years, with 25% vesting after 12 months followed by monthly vesting. The RSUs also vest over four years with similar terms but quarterly vesting for the remaining shares.

GlobeNewswire Inc.

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio announced the grant of stock options to purchase 42,650 shares and RSUs representing 9,050 shares to 9 newly hired employees on April 1, 2026. The stock options have a 10-year term with an exercise price of $17.39 per share and vest over four years, with 25% vesting after 12 months followed by monthly vesting. The grants were made as material inducements to employment under the company's 2023 Inducement Plan.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Sep 19, 20251-for-20reverse split